Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer.

Abstract

From 1 September 1981 to 1 January 1987, 118 patients with FIGO Stage IB, IC, IIA, IIB, and IIC epithelial ovarian cancer were randomized to abdominal irradiation or pelvic irradiation + cyclophosphamide. There was no difference between the regimens with respect to recurrence-free survival (55%) and 4-year overall survival (63%). At routine second-look laparotomy, 16% of patients without clinical detectable tumor showed recurrence. Twenty-five percent of the patients treated with pelvic irradiation + cyclophosphamide had hemorrhagic cystitis, probably caused by radiation damage and cyclophosphamide cystitis. Eight percent had late gastrointestinal symptoms requiring surgery.

• Authors: A Sell, K Bertelsen, J E Andersen, I Strøyer, J Panduro
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 37 Issue 3 Pg. 367-73 (Jun 1990) ISSN: 0090-8258 [Print] United States
• PMID: 2351321 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclophosphamide

Topics

• Abdomen (radiation effects)
• Aged
• Cyclophosphamide (adverse effects, therapeutic use)
• Female
• Humans
• Intestines (drug effects, pathology)
• Laparotomy
• Neoplasm Recurrence, Local
• Ovarian Neoplasms (drug therapy, radiotherapy, surgery)
• Patient Compliance
• Pelvis (radiation effects)
• Radiation Injuries
• Random Allocation
• Reoperation
• Survival Analysis